Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon May 06, 2020 2:30pm
119 Views
Post# 30994266

RE:RE:The message is in the press release

RE:RE:The message is in the press releaseEveryone here keeps focusing on the USA and FDA... what many dont realize is that this solution (ours) is going to be home grown, we dont need to be manaufacturing tests commercially, we dont need to be the selling treatment to the public and we dont need to be developing a vaccine and distributiong it... we just have to come up with the best basics for these things and the big boys take over... our history has been to develop the product.. we dont want or have the capailoities to take it to market... and its interesting you brought up Roche...check out how much Roche is making available to small biotechs, research groups in all the above mentioned needs, They are looking at everyone and anyone. All the big compnaies are looking to develop a test or treatment or vacinne...  we could have many of each avaialble .. we just need to make something that can work and then were out of herre to the next task... 
Bullboard Posts